Pharvaris (PHVS) Cash from Operations Growth (1y) (2021 - 2026)

Pharvaris (PHVS) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 356.73%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 74.39%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 3.23%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Pharvaris 2.22 Bn 1.94 Bn - -41.08%

Historic Data

Download Data
DateValue
Mar 31, 2026 -41.08%
Dec 31, 2025 -18.28%
Sep 30, 2025 1.85%
Jun 30, 2025 -13.84%
Mar 31, 2025 -53.73%
Dec 31, 2024 -45.81%
Sep 30, 2024 -100.00%
Jun 30, 2024 100.00%
Mar 31, 2024 2.69%
Dec 31, 2023 -23.00%
Sep 30, 2023 324,922,255.76%
Jun 30, 2023 -340,632,884.32%
Mar 31, 2023 -34.80%
Dec 31, 2022 -45.61%
Sep 30, 2022 -29.31%
Jun 30, 2022 -2.26%
Mar 31, 2022 -63.12%
Dec 31, 2021 -34.62%
Sep 30, 2021 -53.00%
Jun 30, 2021 -256.20%